diethoxy-methyl-[3-(oxiran-2-ylmethoxy)propyl]silane

We are diethoxy-methyl-[3-(oxiran-2-ylmethoxy)propyl]silane CAS:2897-60-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Chemical Name:diethoxy-methyl-[3-(oxiran-2-ylmethoxy)propyl]silane
CAS.NO:2897-60-1
Synonyms:diethoxy(methyl)[3-(oxiran-2-ylmethoxy)propyl]silane; diethoxy[3-(glycidyloxy)propyl]methylsilane; 3-[Diethoxy(methyl)silyl]propyl Glycidyl Ether;(3-Glycidyloxypropyl)methyldiethoxysilane;
Diethoxy(methyl)(3-(oxiran-2-ylmethoxy)propyl)silane;
Molecular Formula:C11H24O4Si
Molecular Weight:248.39100
 
Physical and Chemical Properties:
Density:0.978;
Boiling point:122-126^oC;
Flash point:122^oC;
Index of Refraction:1.431;
 
Specification:
Appearance:Colorless clear liquid
Purity(GC):≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It can be used to improve dry and wet strength in cured composites reinforced with glass fiber rovings.
It can be used to enhance wet electrical properties of epoxy-based encapsulate and packaging materials.
It can be used to eliminate the need for a separate primer in polysulfide and urethane sealants.
It can be used to improve adhesion in waterborne acrylic sealants and in urethane and epoxy coatings.
 




Related News: This is how an API becomes a medicine.(2-chloro-4-fluorophenyl)methanol This is how an API becomes a medicine.triphenylsilanol CAS:791-31-1;16527-35-8 In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.68239-81-6 In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.